Akèy › Timè Rhabdoid
Etid klinik pou Timè Rhabdoid ap rekrite nan Etazini
17 etid pou Timè Rhabdoid ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Ap rekriteFaz 1
Laj 1 a 30 · Tout sèks · Mizajou Sep 11, 2026 · NCT07087002NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors
Ap rekriteFaz 1
Laj 3 a 25 · Tout sèks · Mizajou Sep 9, 2026 · NCT07664176HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Ap rekriteFaz 1
36 Months – 22 Years · Tout sèks · Mizajou Sep 4, 2026 · NCT03911388B7-H3.CD28Z.CART in CNS Neoplasms
Ap rekriteFaz 1
Laj 2 a 21 · Tout sèks · Mizajou Sep 3, 2026 · NCT07390539Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Ap rekriteFaz 1/2
Jiska laj 26 · Tout sèks · Mizajou Sep 3, 2026 · NCT06465199Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Aug 6, 2026 · NCT04715191C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
Ap rekriteFaz 1
12 Months – 25 Years · Tout sèks · Mizajou Aug 3, 2026 · NCT04099797Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Ap rekriteFaz 1/2
6 Months – 25 Years · Tout sèks · Mizajou Jun 30, 2026 · NCT06625190Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)
Ap rekriteFaz 2
Laj 1 a 39 · Tout sèks · Mizajou Jun 23, 2026 · NCT07447076Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
Ap rekriteFaz 1
Laj 1 a 30 · Tout sèks · Mizajou Jun 17, 2026 · NCT06193759B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou May 19, 2026 · NCT04897321Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou May 19, 2026 · NCT04901702A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Ap rekriteFaz 2
12 Months · Tout sèks · Mizajou May 6, 2026 · NCT05985161Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Ap rekriteFaz 1
Laj 1 a 26 · Tout sèks · Mizajou Apr 13, 2026 · NCT04185038Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Ap rekriteFaz 1
Laj 1 a 26 · Tout sèks · Mizajou Feb 17, 2026 · NCT07148050Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou Nov 3, 2025 · NCT06198296A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Ap rekriteFaz 2
18 Months – 40 Years · Tout sèks · Mizajou Aug 12, 2025 · NCT05135975Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.